Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02628236 · ClinicalTrials.gov registry record · Phase 2
Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)
A Phase 2 study of Keratosis, Actinic, sponsored by DUSA Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 2
- Study locations
NCT02628236 is a Phase 2 study of Keratosis, Actinic that has completed, run by DUSA Pharmaceuticals. The registered enrollment target is 14 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT02628236, a Phase 2 study of Keratosis, Actinic, has completed, sponsored by DUSA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the potential for systemic exposure of aminolevulinic acid (ALA) and protoporphyrin IX (PpIX) when applied topically under occlusion, in a maximal use setting in patients with multiple actinic keratoses (AK) involving the upper extremities.
Conditions Studied
Interventions
- DRUG Aminolevulinic Acid (ALA)
- DEVICE BLU-U
Study Locations (2)
Texas
- DermResearch, Inc. - Austin
- J&J Studies, Inc - College Station
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-02 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02628236
The ClinicalTrials.gov registry entry for NCT02628236 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DUSA Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Keratosis, Actinic appearing as the primary indexed condition, and to 2 interventions - of which Aminolevulinic Acid (ALA) is the first listed.
NCT02628236 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02628236 about?
NCT02628236 is a clinical study titled "Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)". The purpose of this study is to evaluate the potential for systemic exposure of aminolevulinic acid (ALA) and protoporphyrin IX (PpIX) when applied topically under occlusion, in a maximal use setting in patients with multiple actinic keratoses (AK) involving the upper extremities.
What is the current status of trial NCT02628236?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2016-02. Estimated completion is 2016-07.
What conditions does trial NCT02628236 study?
This clinical trial studies the following conditions: Keratosis, Actinic.
What interventions are being tested in trial NCT02628236?
The interventions under investigation include: Aminolevulinic Acid (ALA) (DRUG), BLU-U (DEVICE).
Who is sponsoring clinical trial NCT02628236?
This trial is sponsored by DUSA Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02628236 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratosis, Actinic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.